UNSPSC 51434811: Utibaprilat

This classification denotes an ace inhibitor, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier KN82541NHV. European Medicines Agency schedules Utibaprilat in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00001MIG. Utibaprilat generally arises in the molecular formula C20H27N3O5S.

UNSPSC 51434811 Utibaprilat, a Commodity code, encompasses prescription pharmaceuticals and related medications procured by state and local health systems, fire rescue services, and pharmacy benefit programs. State and local governments buy medications through this code to stock emergency medical supplies, support pharmacy benefit programs, and fulfill direct-to-manufacturer procurement initiatives. Issuing bodies include municipal fire and rescue departments, state health and human services agencies, and multistate cooperative purchasing alliances. The work solicited ranges from small, targeted buys of emergency life-support medications to large-scale multi-state pharmaceutical supply contracts that aggregate purchases across participating jurisdictions and authorized wholesalers.

Recent activity spans Florida, Texas, and the upper Midwest. The City of Tampa's Purchasing Department issued an IFB (Bid No. 26P00188) on April 24, 2026, for Advanced Life Support Medications (Epinephrine, Diltiazem, Adenosine, and Labetalol) to supply Tampa Fire Rescue, with a response deadline of April 8, 2026, an estimated contract value of $40,000, and a one-year term with two optional renewals; the solicitation included a 5 percent bid discount for Small Local Business Enterprises. The Texas Health and Human Services Commission posted an RFI (HHS0017013) on April 3, 2026, to gather market intelligence on direct-to-manufacturer prescription programs for self-insured health plans and state agencies, signaling preliminary procurement planning with no budget or award value disclosed at that stage. The Minnesota Department of Administration's Office of State Procurement, administering the MMCAP cooperative purchasing vehicle, issued an RFP (S1070000015802) on January 20, 2026, with a response deadline of March 26, 2026, for generic multi-source pharmaceuticals and OTC products distributed through authorized wholesalers (AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson Co.) across participating state and local facilities; the contract term is two years with optional extensions, and evaluation weighted price competitiveness at 75 percent with compliance, EDI capability, and administrative-fee acceptance as secondary criteria.